세계의 요로암 시장 보고서(2025년)

Urinary tract cancer encompasses malignancies that can develop in the kidneys, bladder, ureters, or urethra, often leading to symptoms like hematuria (blood in the urine) and pain. Taking preventive measures, such as quitting smoking, avoiding exposure to harmful substances, and promptly addressing urinary tract infections, can help reduce the risk of developing urinary tract cancer.

The primary types of urinary tract cancer include bladder cancer, urethral cancer, ureteric cancer, and renal pelvic cancer. Bladder cancer is characterized by abnormal cell growth in the lining of the bladder, directly affecting the urinary system, as the bladder plays a crucial role in this system. Treatments for bladder cancer typically involve approaches like radical cystectomy, radiation therapy, targeted therapy, chemotherapy, intravenous therapy, radiation therapy, and surgery. Diagnosis is typically conducted through methods such as cystoscopy, transurethral resection of the tumor, imaging tests, urine analyses, and various other techniques. Products for both treatment and diagnosis are distributed through channels such as retail pharmacies and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The urinary tract cancer market research report is one of a series of new reports from The Business Research Company that provides urinary tract cancer market statistics, including urinary tract cancer industry global market size, regional shares, competitors with a urinary tract cancer market share, detailed urinary tract cancer market segments, market trends and opportunities and any further data you may need to thrive in the urinary tract cancer industry. This urinary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinary tract cancer market size has grown rapidly in recent years. It will grow from $3.21 billion in 2024 to $3.84 billion in 2025 at a compound annual growth rate (CAGR) of 19.8%. The growth in the historic period can be attributed to advancements in diagnostics, pharmaceutical developments, awareness and early detection, precision medicine.

The urinary tract cancer market size is expected to see rapid growth in the next few years. It will grow to $7.73 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to immunotherapy advancements, telemedicine and remote monitoring, biomarker research, adjuvant therapies. Major trends in the forecast period include global collaboration, advances in palliative care, comprehensive survivorship programs, patient-centric care.

The forecast of 19.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. oncology care by increasing costs for PD-1/PD-L1 inhibitor therapies imported from Switzerland and China, potentially delaying immunotherapy for bladder cancer and raising oncology department operational costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the prevalence of bladder cancer is set to fuel the growth of the urinary tract cancer market. Bladder cancer is characterized by the development of cancerous cells in the tissues of the urinary bladder, a crucial organ responsible for storing urine before its elimination from the body. This increased prevalence is leading to a greater demand for diagnostic tools, screening methods, and treatment options for individuals affected by urinary tract cancer. For example, in January 2023, a report by the American Cancer Society Inc., a U.S.-based cancer awareness organization, revealed an estimated increase in urinary system cancer cases to 168,560 in 2023, representing a 2.66% rise from 164,190 in 2022 in the United States. Additionally, cases of bladder cancer increased to 83,730 in 2021, a 2.8% increase from 81,400 in 2020. Hence, the growing prevalence of bladder cancer is expected to be a significant driver of the urinary tract cancer market's growth.

The increasing prevalence of urinary tract infections is anticipated to drive the expansion of the urinary tract cancer market in the future. Urinary tract infections result from bacterial infections that can affect various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment and management are required to prevent the spread of infection, which can potentially lead to cancer in multiple ways. For instance, as of January 2023, the National Institute of Health, a U.S.-based public health research agency, reported that urinary tract infections constituted the seventh most common reason for patients to visit an emergency department in the USA, with over 1 million visits annually. Of these cases, 22% (220,000) were classified as complicated UTIs, and approximately 100,000 patients were admitted each year. Hence, the rising prevalence of urinary tract infections is a driving force behind the growth of the urinary tract cancer market.

Leading companies operating in the urinary tract cancer market are increasingly focusing on advancing treatment methods to provide more effective and personalized solutions, gaining a competitive edge in the market. These advancements in urinary tract cancer treatment emphasize precise interventions, harnessing the body's immune system, improving surgical techniques, and tailoring treatments to meet the specific needs of individual patients. For example, in October 2022, UC San Diego Health, a U.S.-based healthcare system, introduced an advanced treatment for patients with low-grade upper tract urothelial cancer (LG-UTUC), a relatively uncommon subtype of urinary system cancer. This innovative treatment offers an alternative approach to the traditional complete kidney removal method, potentially sparing patients from the need for future dialysis or kidney transplants. The therapy involves the administration of Jelmyto, a drug containing mitomycin, a well-known chemotherapy agent, combined with a sterile hydrogel, delivered through guided injections that precisely target the tumor within the urinary system.

In August 2022, Merck & Co., a US-based pharmaceutical company, acquired Seagen for $40 billion. This acquisition allows Merck & Co. to expand its presence in oncology. Seagen Inc., a US-based biotechnology company, specializes in the development of various cancer treatments and drugs, including those for urinary tract cancer.

Major companies operating in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Shionogi & Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Endo International PLC, Seagen Inc., Exelixis Inc., Ferring Pharmaceuticals, Bavarian Nordic, EUSA Pharma, UroGen Pharma Inc., Mersana Therapeutics, Protara Therapeutics Inc., Spectrum Pharmaceuticals, IDL Biotech AB, AroCell AB, ImmunityBio Inc.

North America was the largest region in the urinary tract cancer market in 2024. The regions covered in urinary tract cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urinary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary tract cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgery and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary tract cancer market also includes sales of urinary catheters, cystoscopes, imaging equipment, urine cytology kits, pain relief medications and physical therapy devices which are used in providing diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urinary Tract Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urinary tract cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urinary tract cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The urinary tract cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Bladder Cancer; Urethral Cancer; Ureteric And Renal Pelvic Cancer
• 2) By Treatment: Chemotherapy; Intravesical Therapy; Radiation Therapy; Surgery
• 3) By Diagnostic Techniques: Cystoscopy; Transurethral Resection Of The Tumor; Imaging Tests; Urine Analyses; Other Diagnostic Techniques
• 4) By Distribution Channel: Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Bladder Cancer: Transitional Cell Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma; Other Types
• 2) By Urethral Cancer: Urethral Carcinoma; Other Urethral Tumors
• 3) By Ureteric And Renal Pelvic Cancer: Ureteric Cancer; Renal Pelvic Cancer; Other Types
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck KGaA; Bayer AG; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline PLC (GSK); Eli Lilly and Company; Amgen Inc.; Astellas Pharma Inc.; Eisai Co. Ltd.; Boehringer Ingelheim GmbH; Incyte Corporation; Shionogi & Co. Ltd.; Kyowa Hakko Kirin Co. Ltd; Endo International PLC; Seagen Inc.; Exelixis Inc.; Ferring Pharmaceuticals; Bavarian Nordic; EUSA Pharma; UroGen Pharma Inc.; Mersana Therapeutics; Protara Therapeutics Inc.; Spectrum Pharmaceuticals; IDL Biotech AB; AroCell AB; ImmunityBio Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urinary Tract Cancer Market Characteristics

3. Urinary Tract Cancer Market Trends And Strategies

4. Urinary Tract Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Urinary Tract Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urinary Tract Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urinary Tract Cancer Market Growth Rate Analysis
• 5.4. Global Urinary Tract Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urinary Tract Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urinary Tract Cancer Total Addressable Market (TAM)

6. Urinary Tract Cancer Market Segmentation

• 6.1. Global Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bladder Cancer
• Urethral Cancer
• Ureteric And Renal Pelvic Cancer
• 6.2. Global Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Intravesical Therapy
• Radiation Therapy
• Surgery
• 6.3. Global Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cystoscopy
• Transurethral Resection Of The Tumor
• Imaging Tests
• Urine Analyses
• Other Diagnostic Techniques
• 6.4. Global Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Urinary Tract Cancer Market, Sub-Segmentation Of Bladder Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Transitional Cell Carcinoma
• Squamous Cell Carcinoma
• Adenocarcinoma
• Other Types
• 6.6. Global Urinary Tract Cancer Market, Sub-Segmentation Of Urethral Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Urethral Carcinoma
• Other Urethral Tumors
• 6.7. Global Urinary Tract Cancer Market, Sub-Segmentation Of Ureteric And Renal Pelvic Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ureteric Cancer
• Renal Pelvic Cancer
• Other Types

7. Urinary Tract Cancer Market Regional And Country Analysis

• 7.1. Global Urinary Tract Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urinary Tract Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urinary Tract Cancer Market

• 8.1. Asia-Pacific Urinary Tract Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urinary Tract Cancer Market

• 9.1. China Urinary Tract Cancer Market Overview
• 9.2. China Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urinary Tract Cancer Market

• 10.1. India Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urinary Tract Cancer Market

• 11.1. Japan Urinary Tract Cancer Market Overview
• 11.2. Japan Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urinary Tract Cancer Market

• 12.1. Australia Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urinary Tract Cancer Market

• 13.1. Indonesia Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urinary Tract Cancer Market

• 14.1. South Korea Urinary Tract Cancer Market Overview
• 14.2. South Korea Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urinary Tract Cancer Market

• 15.1. Western Europe Urinary Tract Cancer Market Overview
• 15.2. Western Europe Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urinary Tract Cancer Market

• 16.1. UK Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urinary Tract Cancer Market

• 17.1. Germany Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urinary Tract Cancer Market

• 18.1. France Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urinary Tract Cancer Market

• 19.1. Italy Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urinary Tract Cancer Market

• 20.1. Spain Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urinary Tract Cancer Market

• 21.1. Eastern Europe Urinary Tract Cancer Market Overview
• 21.2. Eastern Europe Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urinary Tract Cancer Market

• 22.1. Russia Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urinary Tract Cancer Market

• 23.1. North America Urinary Tract Cancer Market Overview
• 23.2. North America Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urinary Tract Cancer Market

• 24.1. USA Urinary Tract Cancer Market Overview
• 24.2. USA Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urinary Tract Cancer Market

• 25.1. Canada Urinary Tract Cancer Market Overview
• 25.2. Canada Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urinary Tract Cancer Market

• 26.1. South America Urinary Tract Cancer Market Overview
• 26.2. South America Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urinary Tract Cancer Market

• 27.1. Brazil Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urinary Tract Cancer Market

• 28.1. Middle East Urinary Tract Cancer Market Overview
• 28.2. Middle East Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urinary Tract Cancer Market

• 29.1. Africa Urinary Tract Cancer Market Overview
• 29.2. Africa Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urinary Tract Cancer Market Competitive Landscape And Company Profiles

• 30.1. Urinary Tract Cancer Market Competitive Landscape
• 30.2. Urinary Tract Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Urinary Tract Cancer Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. GlaxoSmithKline PLC (GSK)
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Eisai Co. Ltd.
• 31.9. Boehringer Ingelheim GmbH
• 31.10. Incyte Corporation
• 31.11. Shionogi & Co. Ltd.
• 31.12. Kyowa Hakko Kirin Co. Ltd
• 31.13. Endo International PLC
• 31.14. Seagen Inc.
• 31.15. Exelixis Inc.

32. Global Urinary Tract Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urinary Tract Cancer Market

34. Recent Developments In The Urinary Tract Cancer Market

35. Urinary Tract Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Urinary Tract Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urinary Tract Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urinary Tract Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer